Henkel's valuation now reflects calmer expectations, not a full rerating
Henkel is no longer trading like a business in panic mode. At 12.2x earnings, the market is pricing in more stability than it did when the company posted only 0.9 percent organic growth in 2025 and later cut its full-year outlook to 1.0 to 2.0 percent organic sales growth. Even so, the stock does not yet command a full quality premium. The recent post-earnings move suggests investors want proof that the stabilisation is durable, not just relief that the latest report was better than feared.
Bulls now have a fresh data point: Henkel delivered good organic sales growth in the first quarter of 2026, and management kept its 2026 outlook unchanged at 1.0 to 3.0 percent organic sales growth and low to high single-digit EPS growth. The completed around 1 billion euros share buyback also signals confidence.
The cautious view, though, still matters. Henkel may have stopped the bleeding without restarting a true compounding path. A steadier share price can result from lower fear alone, and the multiple should only expand if that optimism is backed by more execution. For now, stabilisation looks real; a full rerating does not.
Profitability, not headline growth, is the core of the story
The central question is not whether Henkel can look decent in a difficult market. It is whether modest growth and disciplined profitability can compound into something the market values more highly than a simple stabilisation story.
2025 showed that margins and cash still held up
In 2025, Henkel's operating performance was clearer than the headline growth rate suggested. The company produced around 20.5 billion euros of sales while improving profitability, generating about 1.9 billion euros of free cash flow, and delivering EPS of 5.33 euros, up 4.7 percent at constant FX. That matters because a business growing at roughly 1 percent can still create value if margins expand and cash generation remains strong.
That is why the valuation debate is still open. The market is not questioning Henkel's operational discipline. It is questioning whether that discipline deserves only a steady-state multiple or the start of a more meaningful rerating.
Q1 2026 raised the floor, but it did not settle the case
The first quarter added a useful data point: around 5.0 billion euros in sales and organic growth of 1.7 percent, with positive volume and price contributions in both business units. That does not prove a full recovery, but it does weaken the argument that Henkel simply stopped a decline and then slipped again.
Management also kept its 2026 sales outlook at 1.0 to 3.0 percent organic growth and maintained adjusted return on sales of 14.5 to 16.0 percent, alongside low to high single-digit EPS growth. That is the setup investors care about: not rapid revenue expansion, but a business that can grow modestly, defend margins, and still lift earnings.
M&A can help, but organic consistency still has to do the heavy lifting
Henkel's M&A activity adds another layer to the bull case. The company said earlier this year that its recent transactions represent around 1.6 billion euros in sales, with three of five deals already closed. If those acquisitions integrate cleanly, they can add to both sales and earnings without Henkel having to rely only on internal demand recovery.
The caution is straightforward. M&A can muddy the picture, and tariff uncertainty still weighs on the outlook, as management showed when it updated last year's guidance to 1.0 to 2.0 percent organic sales growth. The right test, then, is not whether deals exist on paper. It is whether Henkel can keep organic growth above the low-single-digit floor and then add acquired growth on top.
Cheap, or cheap-looking?
That distinction matters now. The market is deciding whether Henkel deserves a modest multiple expansion or whether the stock is simply compensating investors for waiting.
A low P/E only becomes more attractive over time if it is paired with earnings that can compound. Henkel currently offers a useful split: a 3.12% dividend gives investors time value, while external growth estimates imply 4 percent annual earnings growth. That is not a fast-growth profile. It looks more like a good operator in a normal market.
The bridge from cheap-looking to genuinely cheap is profitability. Henkel is not asking investors to trust a distant turnaround. It has already shown it can protect margins, with a 14.8 percent EBIT margin in 2025 and a management target range of 14.5 to 16.0 percent adjusted return on sales. If that margin strength holds, modest top-line progress can still produce a healthier earnings compounder than the headline growth rate implies. If margins slip, the lower multiple may simply have been fair pricing for a business still proving its resilience.
What would support a rerating
- Henkel meets or beats its 14.5 to 16.0 percent adjusted return-on-sales target.
- Management keeps low to high single-digit EPS growth intact as the year progresses.
- Acquisitions add cleanly, without an obvious drag on profitability.
What would argue for patience
- Sales improve only slightly while margins fail to follow through.
- The company narrows its return-on-sales target range.
- Growth becomes more deal-dependent because organic demand does not build on the Q1 2026 improvement.
For patient investors, Henkel looks more like a conditional upside setup than an obvious bargain. If earnings power stays near the company's margin target, the stock can move from stable to better valued than the market currently gives it credit for. If that profitability proof weakens, the yield is compensation for patience, not evidence that a rerating is owed.